Repeat Transcatheter Aortic Valve Replacement for Transcatheter Prosthesis Dysfunction.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
28 04 2020
Historique:
received: 22 11 2019
revised: 15 01 2020
accepted: 14 02 2020
entrez: 25 4 2020
pubmed: 25 4 2020
medline: 2 1 2021
Statut: ppublish

Résumé

Transcatheter aortic valve replacement (TAVR) use is increasing in patients with longer life expectancy, yet robust data on the durability of transcatheter heart valves (THVs) are limited. Redo-TAVR may play a key strategy in treating patients in whom THVs fail. The authors sought to examine outcomes following redo-TAVR. The Redo-TAVR registry collected data on consecutive patients who underwent redo-TAVR at 37 centers. Patients were classified as probable TAVR failure or probable THV failure if they presented within or beyond 1 year of their index TAVR, respectively. Among 63,876 TAVR procedures, 212 consecutive redo-TAVR procedures were identified (0.33%): 74 within and 138 beyond 1 year of the initial procedure. For these 2 groups, TAVR-to-redo-TAVR time was 68 (38 to 154) days and 5 (3 to 6) years. The indication for redo-TAVR was THV stenosis in 12 (16.2%) and 51 (37.0%) (p = 0.002) and regurgitation or combined stenosis-regurgitation in 62 (83.8%) and 86 (62.3%) (p = 0.028), respectively. Device success using VARC-2 criteria was achieved in 180 patients (85.1%); most failures were attributable to high residual gradients (14.1%) or regurgitation (8.9%). At 30-day and 1-year follow-up, residual gradients were 12.6 ± 7.5 mm Hg and 12.9 ± 9.0 mm Hg; valve area 1.63 ± 0.61 cm Redo-TAVR is a relatively safe and effective option for selected patients with valve dysfunction after TAVR. These results are important for applicability of TAVR in patients with long life expectancy in whom THV durability may be a concern.

Sections du résumé

BACKGROUND
Transcatheter aortic valve replacement (TAVR) use is increasing in patients with longer life expectancy, yet robust data on the durability of transcatheter heart valves (THVs) are limited. Redo-TAVR may play a key strategy in treating patients in whom THVs fail.
OBJECTIVES
The authors sought to examine outcomes following redo-TAVR.
METHODS
The Redo-TAVR registry collected data on consecutive patients who underwent redo-TAVR at 37 centers. Patients were classified as probable TAVR failure or probable THV failure if they presented within or beyond 1 year of their index TAVR, respectively.
RESULTS
Among 63,876 TAVR procedures, 212 consecutive redo-TAVR procedures were identified (0.33%): 74 within and 138 beyond 1 year of the initial procedure. For these 2 groups, TAVR-to-redo-TAVR time was 68 (38 to 154) days and 5 (3 to 6) years. The indication for redo-TAVR was THV stenosis in 12 (16.2%) and 51 (37.0%) (p = 0.002) and regurgitation or combined stenosis-regurgitation in 62 (83.8%) and 86 (62.3%) (p = 0.028), respectively. Device success using VARC-2 criteria was achieved in 180 patients (85.1%); most failures were attributable to high residual gradients (14.1%) or regurgitation (8.9%). At 30-day and 1-year follow-up, residual gradients were 12.6 ± 7.5 mm Hg and 12.9 ± 9.0 mm Hg; valve area 1.63 ± 0.61 cm
CONCLUSIONS
Redo-TAVR is a relatively safe and effective option for selected patients with valve dysfunction after TAVR. These results are important for applicability of TAVR in patients with long life expectancy in whom THV durability may be a concern.

Identifiants

pubmed: 32327098
pii: S0735-1097(20)34458-2
doi: 10.1016/j.jacc.2020.02.051
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1882-1893

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Uri Landes (U)

Centre for Cardiovascular Innovation Centre for Heart Valve Innovation, St. Paul's and Vancouver General Hospital, Vancouver, British Columbia, Canada; Rabin Medical Center, Tel-Aviv University, Tel-Aviv, Israel.

John G Webb (JG)

Centre for Cardiovascular Innovation Centre for Heart Valve Innovation, St. Paul's and Vancouver General Hospital, Vancouver, British Columbia, Canada. Electronic address: johngraydonwebb@gmail.com.

Ole De Backer (O)

Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Lars Sondergaard (L)

Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Mohamed Abdel-Wahab (M)

Herzzentrum Leipzig, Leipzig, Germany.

Lisa Crusius (L)

Herzzentrum Leipzig, Leipzig, Germany.

Won-Keun Kim (WK)

Kerckhoff Heart Center, Bad Nauheim, Germany.

Christian Hamm (C)

Kerckhoff Heart Center, Bad Nauheim, Germany.

Nicola Buzzatti (N)

San Raffaele Scientific Institute, Milan, Italy.

Matteo Montorfano (M)

San Raffaele Scientific Institute, Milan, Italy.

Sebastian Ludwig (S)

University Heart Center Hamburg, Hamburg, Germany.

Niklas Schofer (N)

University Heart Center Hamburg, Hamburg, Germany.

Lisa Voigtlaender (L)

University Heart Center Hamburg, Hamburg, Germany.

Mayra Guerrero (M)

Mayo Clinic, Rochester, Minnesota.

Abdallah El Sabbagh (A)

Mayo Clinic, Rochester, Minnesota.

Josep Rodés-Cabau (J)

Quebec Heart and Lung Institute, Quebec, Quebec, Canada.

Leonardo Guimaraes (L)

Quebec Heart and Lung Institute, Quebec, Quebec, Canada.

Ran Kornowski (R)

Rabin Medical Center, Tel-Aviv University, Tel-Aviv, Israel.

Pablo Codner (P)

Rabin Medical Center, Tel-Aviv University, Tel-Aviv, Israel.

Taishi Okuno (T)

University Hospital of Bern, Bern, Switzerland.

Thomas Pilgrim (T)

University Hospital of Bern, Bern, Switzerland.

Claudia Fiorina (C)

Spedali Civili Brescia, Brescia, Italy.

Antonio Colombo (A)

Maria Cecilia Hospital, Cotignola, Ravenna, Italy.

Antonio Mangieri (A)

Maria Cecilia Hospital, Cotignola, Ravenna, Italy.

Helene Eltchaninoff (H)

Normandie Univ, UNIROUEN, INSERM U1096, Rouen University Hospital, Department of Cardiology, FHU REMOD-VHF, F76000, Rouen, France.

Luis Nombela-Franco (L)

Cardiovascular Institute, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.

Maarten P H Van Wiechen (MPH)

Erasmus University Medical Center, Rotterdam, the Netherlands.

Nicolas M Van Mieghem (NM)

Erasmus University Medical Center, Rotterdam, the Netherlands.

Didier Tchétché (D)

Clinique Pasteur, Toulouse, France.

Wolfgang H Schoels (WH)

Herzzentrum Duisburg, Duisburg, Germany.

Matthias Kullmer (M)

Herzzentrum Duisburg, Duisburg, Germany.

Corrado Tamburino (C)

A.O.U. Policlinico Vittorio Emanuele, University of Catania, Catania, Italy.

Jan-Malte Sinning (JM)

University Hospital Bonn, Bonn, Germany.

Baravan Al-Kassou (B)

University Hospital Bonn, Bonn, Germany.

Gidon Y Perlman (GY)

Hadassah Medical Center, Jerusalem, Israel.

Haim Danenberg (H)

Hadassah Medical Center, Jerusalem, Israel.

Alfonso Ielasi (A)

S. Ambrogio Cardio-Thoracic Center, Milan, Italy.

Chiara Fraccaro (C)

University Hospital of Padova, Padova, Italy.

Giuseppe Tarantini (G)

University Hospital of Padova, Padova, Italy.

Federico De Marco (F)

IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.

Guy Witberg (G)

Rabin Medical Center, Tel-Aviv University, Tel-Aviv, Israel; St. Thomas' Hospital Campus, London, United Kingdom.

Simon R Redwood (SR)

St. Thomas' Hospital Campus, London, United Kingdom.

John C Lisko (JC)

Emory University Hospital, Atlanta, Georgia.

Vasilis C Babaliaros (VC)

Emory University Hospital, Atlanta, Georgia.

Mika Laine (M)

Helsinki University Central Hospital, Helsinki, Finland.

Roberto Nerla (R)

Humanitas Gavazzeni, Bergamo, Italy.

Fausto Castriota (F)

Humanitas Gavazzeni, Bergamo, Italy.

Ariel Finkelstein (A)

Tel-Aviv Medical Center, Tel-Aviv, Israel.

Itamar Loewenstein (I)

Tel-Aviv Medical Center, Tel-Aviv, Israel.

Amnon Eitan (A)

Carmel Medical Center, Haifa, Israel.

Ronen Jaffe (R)

Carmel Medical Center, Haifa, Israel.

Philipp Ruile (P)

University Heart Center Freiburg, Bad Krozingen, Germany.

Franz J Neumann (FJ)

University Heart Center Freiburg, Bad Krozingen, Germany.

Nicolo Piazza (N)

McGill University Health Center, Montreal, Quebec, Canada.

Hind Alosaimi (H)

McGill University Health Center, Montreal, Quebec, Canada.

Horst Sievert (H)

Cardiovascular Center, Frankfurt, Germany.

Kolja Sievert (K)

Cardiovascular Center, Frankfurt, Germany.

Marco Russo (M)

Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.

Martin Andreas (M)

Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria.

Matjaz Bunc (M)

University Medical Centre Ljubljana, Ljubljana, Slovenia.

Azeem Latib (A)

Montefiore Medical Center, New York, New York.

Rebecca Govdfrey (R)

Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom.

David Hildick-Smith (D)

Brighton & Sussex University Hospitals NHS Trust, Brighton, United Kingdom.

Janarthanan Sathananthan (J)

Centre for Cardiovascular Innovation Centre for Heart Valve Innovation, St. Paul's and Vancouver General Hospital, Vancouver, British Columbia, Canada.

Mark Hensey (M)

Centre for Cardiovascular Innovation Centre for Heart Valve Innovation, St. Paul's and Vancouver General Hospital, Vancouver, British Columbia, Canada.

Abdullah Alkhodair (A)

Centre for Cardiovascular Innovation Centre for Heart Valve Innovation, St. Paul's and Vancouver General Hospital, Vancouver, British Columbia, Canada.

Philipp Blanke (P)

Centre for Cardiovascular Innovation Centre for Heart Valve Innovation, St. Paul's and Vancouver General Hospital, Vancouver, British Columbia, Canada.

Jonathon Leipsic (J)

Centre for Cardiovascular Innovation Centre for Heart Valve Innovation, St. Paul's and Vancouver General Hospital, Vancouver, British Columbia, Canada.

David A Wood (DA)

Centre for Cardiovascular Innovation Centre for Heart Valve Innovation, St. Paul's and Vancouver General Hospital, Vancouver, British Columbia, Canada.

Tamim M Nazif (TM)

Columbia University Medical Center, New York, New York.

Susheel Kodali (S)

Columbia University Medical Center, New York, New York.

Martin B Leon (MB)

Columbia University Medical Center, New York, New York.

Marco Barbanti (M)

A.O.U. Policlinico Vittorio Emanuele, University of Catania, Catania, Italy. Electronic address: https://twitter.com/barbanti_marco.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH